[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgical-site-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgical-site-infection":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,42,79,109,134,160,184,216,246,275,305,336,368,393,415,441,465,486,512,539,561,582,614,637,658],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100616883","local-subcutaneous-gentamicin-for-prevention-of-surgical-site-infection-after-elective-cesarean-section-100616883",false,"NCT07311395","Local Subcutaneous Gentamicin for Prevention of Surgical Site Infection After Elective Cesarean Section","Local Subcutaneous Administration of Gentamicin for the Prevention of Surgical Site Infection Following Elective Cesarean Section: A Randomized Controlled Pilot Study.","Inclusion Criteria:\n\n* Women aged 18 years and older.\n* Undergoing elective cesarean section.\n* Gestational age \\>= 24 weeks.\n* Planned postoperative follow-up of 30 days.\n* Eligible for standard antibiotic prophylaxis according to institutional protocol.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Known allergy of hypersensitivity to aminoglycosides.\n* Known allergy of hypersensitivity to systemic antibiotic prophylaxis agents.\n* Current or planned use of immunomodulatory or immunosuppressive therapy.\n* Requirement for therapeutic ( non- prophylactic) antibiotic treatment at the time of surgery.\n* Active infection or clinical condition requiring antibiotic treatment.\n* Inability or unwillingness to comply with study procedures or follow-up.",true,"FEMALE","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate whether local subcutaneous administration of gentamicin reduces the incidence of surgical site infection (SSI) following elective cesarean section. The study will also assess the safety of local gentamicin administration. The main questions this study aims to answer are:\n\n* Does local subcutaneous administration of gentamicin reduce the rate of superficial and deep surgical site infections within 30 days after elective cesarean delivery?\n* Are there differences between groups in postoperative complications, including wound healing, fever, need for additional antibiotic treatment, or hospital readmission?\n\nResearchers will compare women who receive local subcutaneous gentamicin at the surgical site in addition to standard antibiotic prophylaxis to women who receive standard antibiotic prophylaxis alone.\n\nParticipants will:\n\n* Undergo an elective cesarean section according to standard clinical practice\n* Receive either local subcutaneous gentamicin administration or no local antibiotic administration, in addition to standard systemic antibiotic prophylaxis\n* Be followed clinically for signs of surgical site infection and other postoperative complications during hospitalization and at follow-up visits up to 30 days after surgery",[28],"Surgical Site Infection","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-26","ACTUAL",{"date":35,"type":33},"2025-12-08",{"date":37,"type":22},"2027-01-07",{"name":39,"class":40},"Western Galilee Hospital-Nahariya","OTHER_GOV",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100626681","post-amputation-stump-infection-as-a-predictor-of-persistent-residual-limb-pain-a-prospective-cohort-study-100626681","NCT07438795","Post-Amputation Stump Infection as a Predictor of Persistent Residual Limb Pain: A Prospective Cohort Study","INF-STUMP-PAIN","Inclusion Criteria:\n\n* Traumatic upper or lower limb amputation\n* Enrollment within 4 weeks after surgery\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Pre-existing chronic pain in the affected limb\n* Severe cognitive impairment\n* Terminal illness limiting follow-up\n* Refusal or inability to complete follow-up assessments","ALL","60 Years",{"count":52,"type":22},150,"6 Months","OBSERVATIONAL","Persistent residual limb pain is common after traumatic amputation and significantly impairs rehabilitation and prosthetic use. Postoperative stump infection may contribute to peripheral nerve sensitization, scar fibrosis, and long-term pain persistence. This prospective cohort study aims to determine whether early post-amputation stump infection independently predicts persistent clinically significant residual limb pain at 3 and 6 months after surgery.",[57,58,59,28,60],"Residual Limb Pain","Stump Pain","Post-Amputation Pain","Phantom Limb Pain (PLP)",[62,63,64,65,66,67,68],"Traumatic amputation","stump infection","residual limb pain","chronic pain","surgical site infection","blast injury","neuropathic pain","NOT_YET_RECRUITING","2026-06-01",{"date":72,"type":33},"2026-06-03",{"date":30,"type":22},{"date":75,"type":22},"2026-12-23",{"name":77,"class":78},"Ukrainian Society of Regional Anesthesia and Pain Therapy","OTHER",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100631955","phase-4-innovative-sternal-closure-techniques-evaluating-stratafix-and-dermabond-for-reduced-complications-in-cabg-patients-100631955","NCT07507409","Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients","Inclusion Criteria:\n\n\\- Patients aged 18 years and older undergoing CABG surgery.\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the trial.\n* Patients who do not read or speak English.\n* Patient with allergy to surgical adhesives or sutures",{"count":86,"type":22},401,[88],"PHASE4","The goal of this clinical trial is to learn if a new method of closing the breastbone after heart bypass surgery can improve healing and reduce complications in adults undergoing coronary artery bypass graft (CABG) surgery.\n\nThe main questions it aims to answer are:\n\nDoes this new closure method reduce infections and wound reopening? Does it improve healing, recovery, and overall patient outcomes?\n\nResearchers will compare patients who receive the new closure method to past patients who received the standard method to see if outcomes are better.\n\nParticipants will:\n\nReceive the new closure method during their surgery (as part of standard care) Be followed during their normal recovery up to their 6-week follow-up visit Complete a short quality-of-life questionnaire (about 10 minutes) Have their recovery assessed, including healing, complications, and hospital use\n\nResearchers will also look at quality of life, heart complications, hospital readmissions, antibiotic use, scar appearance, and overall costs to understand the full impact of the new method.",[91,28,92,93],"Cardiovascular Disease","Superficial Sternal Wound Infection","Mediastinitis",[95,96,97,98,99],"STRATAFIX","DERMABOND","Sternal Closure","Suture","CABG","2026-04-07",{"date":102,"type":33},"2026-04-13",{"date":104,"type":22},"2026-05-01",{"date":106,"type":22},"2028-05-01",{"name":108,"class":78},"Unity Health Toronto",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":41},"100582883","chlorhexidine-gluconate-versus-saline-for-flushing-the-surgical-area-during-colorectal-cancer-surgery-100582883","NCT06869096","Chlorhexidine Gluconate Versus Saline for Flushing the Surgical Area During Colorectal Cancer Surgery","A Comparative Study of Chlorhexidine Versus Saline Irrigation of the Surgical Area During Colorectal Cancer Surgery: a Multicenter, Stratified Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients aged 18-85 years,\n2. Patients with surgically resectable colorectal tumors confirmed by CT\u002FMRI before surgery\n3. All patients had a performance status score of 0 or 1 in the Eastern Tumor Cooperative group\n4. American Society of Anesthesiology grade I-III\n\nExclusion Criteria:\n\n1. The tumor may have distant metastasis\n2. History of previous abdominal surgery\n3. The patient has a history of other malignant tumors diagnosed in the past 5 years and has received radiotherapy and chemotherapy in the past\n4. There are obvious contraindications to surgery (obvious abnormal liver and kidney function, pregnancy)\n5. Participated in other clinical trials within the past 6 months","85 Years",{"count":118,"type":22},532,[25],"The aim of this study was to compare the effectiveness of chlorhexidine versus saline in flushing the surgical area during colorectal cancer surgery. The primary outcomes included surgical site infection, postoperative complication rates, et al.",[122,28,123,124],"Colorectal Cancer","Chlorhexidine","Complications","2026-03-29",{"date":127,"type":33},"2026-03-31",{"date":129,"type":33},"2024-07-02",{"date":131,"type":22},"2026-12-31",{"name":133,"class":40},"Nanchong Central Hospital",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":143,"conditions":144,"keywords":149,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":158,"locationsCount":41},"100631531","investigating-the-impact-of-cold-atmospheric-plasma-treatment-on-wound-healing-at-cannulation-sites-in-patients-following-extracorporeal-life-support-100631531","NCT07501897","Investigating the Impact of Cold Atmospheric Plasma Treatment on Wound Healing at Cannulation Sites in Patients Following Extracorporeal Life Support","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Receiving extracorporeal life support (ECLS)\n* Presence of cannulation site wound requiring wound care\n\nExclusion Criteria:\n\n* Pre-existing severe dermatological conditions at the cannulation site\n* Severe coagulopathy precluding local intervention\n* Concurrent receipt of other experimental wound treatments\n* Life expectancy \\\u003C 48 hours",{"count":141,"type":22},65,[25],"This study aims to evaluate a new wound treatment called cold atmospheric plasma (CAP) for patients receiving extracorporeal life support (ECLS). Patients on extracorporeal life support (ECLS) often develop wounds at the sites where tubes are inserted, and these wounds can be difficult to heal and prone to infection.\n\ncold atmospheric plasma (CAP) is a gentle, non-heat treatment that can kill bacteria, reduce inflammation, and promote wound healing. In this study, patients will be randomly assigned to receive either standard wound care alone or standard care plus cold atmospheric plasma (CAP) treatment.\n\nResearchers will compare both groups to see whether cold atmospheric plasma (CAP) can reduce infection, improve healing speed, and decrease the need for additional procedures. The study will also monitor safety to ensure the treatment is well tolerated.\n\nThe goal is to find a more effective and safe way to improve wound healing in critically ill patients.",[145,146,28,147,148],"ExtraCorporeal Life Support (ECLS)","Wound Infection","Delayed Wound Healing","Biofilm-Associated Infection",[150,151],"Extracorporeal Life Support","cold atmospheric plasma","2026-03-25",{"date":154,"type":33},"2026-03-30",{"date":156,"type":33},"2026-03-12",{"date":131,"type":22},{"name":159,"class":78},"National Taiwan University Hospital",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100473643","phase-4-duration-of-cardiac-antimicrobial-prophylaxis-outcomes-study-100473643","NCT05447559","Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study","Multicentre, Adaptive, Double-blind, Three-arm, Placebo-controlled, Noninferiority Trial Examining Antimicrobial Prophylaxis Duration in Cardiac Surgery","CALIPSO","Inclusion Criteria:\n\n\\- Adult patients undergoing cardiac surgery involving a median sternotomy\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* American Society of Anesthesiology (ASA) 5\n* Subjects with GFR \\\u003C40mL\u002Fmin\u002F1.73m2 or those requiring continuous renal replacement therapy, haemodialysis or peritoneal dialysis\n* Surgery for suspected or proven endocarditis or deep sternal wound infection\n* Documented cefazolin hypersensitivity\n* Documented methicillin resistant Staphylococcus aureus (MRSA) colonisation or infection in the 12-months prior to index surgery\n* Cardiac transplantation\n* Procedures involving insertion ventricular assist device or mechanical circulatory support device\n* Procedures not involving a median sternotomy\n* Patients previously enrolled and randomised to the CALIPSO trial",{"count":169,"type":22},9180,[88],"This multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial will compare the incidence of surgical site infection and other healthcare associated infections, health economic and microbiological impact after intraoperative only (Arm A), to 24 hours (Arm B) and, to 48 hours (Arm C) of IV cefazolin and placebo postoperative surgical antimicrobial prophylaxis in patients undergoing cardiac surgery",[28],[174],"Cardiac surgery","2026-03-22",{"date":152,"type":33},{"date":178,"type":33},"2023-02-07",{"date":180,"type":22},"2028-06",{"name":182,"class":78},"Monash University",27,{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":192,"targetDuration":194,"studyType":54,"phases":4,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":215},"100513553","novosyn-chd-vs-polyglactin-910-suture-to-close-wounds-after-emergency-or-elective-laparotomy-or-laparoscopic-surgery-100513553","NCT05966961","Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery","'All Comer'\u002F'Real-world' Registry-based Randomized, Prospective, Multicenter Clinical Trial to Evaluate the Incidence of Complications Using Novosyn® CHD Suture Versus Polyglactin 910 Suture to Close the Wound After Emergency or Elective Laparotomy or Laparoscopic Surgery","POLYNOVO-CHD","Inclusion Criteria:\n\n* Patients undergoing an emergency or elective laparotomy or laparoscopic surgery.\n* Written informed consent\n* Age≥ 18 years\n* Not incapacitated patient\n\nExclusion Criteria:\n\n* No exclusion criteria except patients with allergy or hypersensitivity to chlorhexidine",{"count":193,"type":22},2998,"30 Days","The aim of the study is to elucidate, if the colonization of bacteria is lower on the Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by the incidence of surgical site infections (SSI: A1 and A2). The results of this registry will generate further clinical evidence for the use and the benefit of a Chlorhexidine coated suture used to close the wound after an emergency or elective laparoscopic or laparotomy surgery. The benefit for individual patients lies in the early diagnosis of complications and in the optimized postoperative controls of a clinical study.",[28],[198,199,200,201,202,203,204],"Chlorhexidine coated suture","emergency laparoscopic surgery","emergency laparotomy surgery","elective laparoscopic surgery","elective laparotomy surgery","Novosyn®","Polyglactin 910","2026-03-05",{"date":207,"type":33},"2026-03-06",{"date":209,"type":33},"2023-09-18",{"date":211,"type":22},"2028-12",{"name":213,"class":214},"Aesculap AG","INDUSTRY",4,{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":230,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":41},"100418223","studying-how-outpatient-water-affects-risks-with-drains-shower-study-100418223","NCT04725916","Studying How Outpatient Water affEcts Risks With Drains (SHOWER Study)","SHOWER","Inclusion Criteria:\n\n* Patients having one of the following procedures at Geisinger Medical Center in which drains are placed\n\n  * Breast reduction\n  * Lower panniculectomy\n  * Fleur-de-lis panniculectomy\n* ≥18 years of age\n* Able and willing to provide consent\n\nExclusion Criteria:\n\n* Patients on antibiotics at the time of surgery\n* Patients sent home on antibiotics after surgery\n* Patients who work in healthcare with direct patient contact\n* Patients having a panniculectomy to be eligible for a kidney transplant\n* Patients having a ventral hernia repair at the time of the panniculectomy\n* Patients admitted to the hospital for \\>1 night",{"count":21,"type":22},[25],"This is a prospective randomized, controlled, unblinded, interventional feasibility study to evaluate if showering with post operative drains in place leads to an increase in complications. The patients included in the study will be those undergoing breast reductions and panniculectomies at Geisinger Medical Center. The patients will be randomized post operatively into one of two groups: 1) patients instructed to shower with drains in place, and 2) patients instructed not to shower while they have drains in place.",[227,228,28,229],"Postoperative Wound Infection","Postoperative Complications","Drain Site Complication",[231,232,233,234,235,236],"Panniculectomy","Breast reduction surgery","Postoperative showering","Surgical drain","Fleur-de-lis panniculectomy","Massive weight loss surgery","2026-02-18",{"date":239,"type":33},"2026-02-20",{"date":241,"type":33},"2022-02-23",{"date":243,"type":22},"2027-07-15",{"name":245,"class":78},"Sean Devitt",{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":49,"minAge":4,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":261,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":41},"100619601","prevention-of-surgical-site-infection-in-open-paediatric-groin-surgeries-using-intravenous-prophylactic-antibiotics-and-antimicrobial-coated-sutures-100619601","NCT07346742","Prevention of Surgical Site Infection in Open Paediatric Groin Surgeries Using Intravenous Prophylactic Antibiotics and Antimicrobial-coated Sutures","Intravenous Prophylactic Antibiotics and Antimicrobial-Coated Sutures in Preventing Surgical Site Infection in Open Paediatric Groin Surgeries: A 3-arm Randomized Controlled Trial","Inclusion Criteria:\n\n* All patients with clinical conditions requiring daycase open groin surgery\n\nExclusion Criteria:\n\n1. Re-operations\n2. Immunocompromised patients\n3. Malnourished patients\n4. Complicated groin pathologies e,g obstructed inguinal hernia\n5. History of antibiotic usage in the last seven days","15 Years",{"count":255,"type":22},174,[25],"The goal of this clinical trial is to learn if the use of prophylactic antibiotics and antimicrobial-coated sutures can prevent surgical site infection in children undergoing open groin surgeries. The main question it aims to answer is:\n\n• Does the use of intravenous prophylactic antibiotics or antimicrobial-coated sutures significantly reduce the occurrence of surgical site infection in children undergoing open groin surgeries?\n\nResearchers will compare no antibiotic use to the use of intravenous prophylactic antibiotics, or antimicrobial-coated sutures to see if the use of intravenous prophylactic antibiotics and antimicrobial-coated sutures significantly reduces the occurrence of surgical site infection following open groin surgeries in children.\n\nParticipants will:\n\n* Undergo open groin surgery with either the use of intravenous prophylactic antibiotic or antimicrobial-coated sutures or without antibiotic use\n* Visit the clinic on postoperative days 5, 13 and 30 for review of the surgical wounds for any sign of infection.",[259,260,28],"Inguinal Hernia","Hydroceles",[262,263,264,265],"Paediatric groin surgeries","Intravenous prophylactic antibiotics","Antimicrobial-coated sutures","Double blinded randomized controlled trial","2026-01-08",{"date":268,"type":33},"2026-01-16",{"date":270,"type":33},"2025-03-09",{"date":272,"type":22},"2026-02-27",{"name":274,"class":78},"Olawumi Olajide",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":291,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":304},"100593243","treating-emergency-laparotomy-incisions-with-negative-pressure-wound-therapy-100593243","NCT07003906","Treating Emergency Laparotomy Incisions With Negative Pressure Wound Therapy","TELIN","Inclusion Criteria:\n\n* ≥18 years old\n* Written informed consent\n* \\>10 cm midline incision with primary skin closure\n* Emergency laparotomy\n\nExclusion Criteria:\n\n* Not able to consent (e.g. dementia, impaired cognitive function, unconscious)\n* Subjects not possible to follow up as assessed by the Investigator\n* Allergy to dressing material\n* Pregnancy or breastfeeding (females of childbearing potential)\n* Previous enrolment in the current study\n* Expected reoperation with 28 days of index laparotomy\n* Emergency laparotomy within 3 months",{"count":283,"type":22},720,[25],"The goal of this clinical trial is to investigate Negative Pressure Wound Therapy (NPWT) in adults undergoing emergency laparotomy. The main question it aims to answer is:\n\nDoes NPWT decrease wound complications?\n\nResearchers will compare it against regular dressings to see if NPWT is superior.",[287,288,28,289,290],"Surgical Incision","Wound Dehiscence","Incisional Hernia","Quality of Life",[292,293,294],"emergency surgery","negative pressure wound therapy","randomised controlled trial","2025-12-18",{"date":297,"type":33},"2025-12-26",{"date":299,"type":33},"2025-12-16",{"date":301,"type":22},"2035-12",{"name":303,"class":78},"Uppsala University",6,{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":41},"100544053","phase-3-diluted-aqueous-povidone-iodine-compared-to-saline-to-decrease-surgical-site-infections-100544053","NCT06363877","Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections","Wound Irrigation and Peritoneal Lavage With Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections","Inclusion Criteria:\n\n* 18 to 80 years of age\n* undergoing an exploratory laparotomy for Centers for Disease Control class II and III wounds\n\nExclusion Criteria:\n\n* Pregnancy\n* Preoperative abdominal wall skin\u002Fsoft tissue infection\n* Iodine allergy\n* Patients unlikely to survive beyond 30 days\n* Patients with mesh placement or placement of a foreign body except for drains","80 Years",{"count":314,"type":22},1100,[316],"PHASE3","This is a multicenter randomized controlled trial of 1100 patients to evaluate the superiority of combined intraoperative wound irrigation with intraoperative peritoneal lavage with dilute aqueous povidone-iodine compared to normal saline in male and female patients between the ages of 18 and 80 years old undergoing emergency laparotomies with Centers for Disease Control (CDC) class 2 and 3 wounds.",[28],[320,321,322,323,324,325,326],"Intraoperative Wound Irrigation","Intraoperative Peritoneal Lavage","Povidone-Iodine","Normal Saline","Exploratory Laparotomy","Clean Contaminated Wounds","Contaminated Wounds","2025-11-17",{"date":329,"type":33},"2025-11-19",{"date":331,"type":33},"2024-06-03",{"date":333,"type":22},"2026-11",{"name":335,"class":78},"Loma Linda University",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":351,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":364,"leadSponsor":366,"locationsCount":215},"100606827","phase-4-gut-decolonisation-with-neomycinmetronidazole-or-rifaximin-before-colon-surgery-100606827","NCT07180615","Gut Decolonisation With Neomycin\u002FMetronidazole or Rifaximin Before Colon Surgery","Neomycine\u002FMetronidazole- vs Rifaximin-based Gut Decolonisation Prior to Colon Surgery: a Randomized Multicenter Trial","NeoRiDe","Inclusion Criteria:\n\n* aged ≥ 18 years\n* undergoind planned colon surgery\n* colon surgery will be included in Swissnoso SSI surveillance\n* informed consent\n\nExclusion Criteria:\n\n* contraindications and\u002For intolerance to one of the study compounds\n* patients with underlying active infection (wound contamination class IV) at the timepoint of incision\n* pregnant women\n* unable to follow study protocol",{"count":345,"type":22},458,[88],"The goal of this clinical trial is to find out if a gut cleaning using Rifaximin works as well as the usual treatment with Neomycin and Metronidazole to prevent infections after colon surgery. The study includes adult patients who will have colon surgery.\n\nThe main question it aims to answer are:\n\n-Does the Rifaximin treatment prevent surgical site infections as well as the Neomycin\u002FMetronidazole treatment?\n\nOther things the study will look at:\n\n* How often infections happen, stratified on how deep they are, the type of surgery the patients got, or if bowel cleaning was done before surgery.\n* How many people will die after surgery\n* How long people stay in hospital\n\nParticipants will:\n\n* Take either Rifaximin or Neomycin\u002FMetronidazole one day before surgery to clean their gut\n* Keep a diary until the surgery to record medication intake and any side effects\n* Be contacted by phone 30 days after surgery to ask about their condition and any side effects,",[28,349,350],"Colon Surgery","Surgical Site Infections",[352,66,353,354,355,356,357,358,359],"SSI","Metronidazol","flagyl","neomycine","rifaximin","colon surgery","antibiotics","preoperative decolonisation","2025-09-11",{"date":362,"type":33},"2025-09-18",{"date":70,"type":22},{"date":365,"type":22},"2029-06-30",{"name":367,"class":78},"Universität Luzern",{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":41},"100602987","ai-algorithm-for-surveillance-of-deep-surgical-site-infections-after-elective-colorectal-surgery-100602987","NCT07130656","AI Algorithm for Surveillance of Deep Surgical Site Infections After Elective Colorectal Surgery.","A Novel AI Algorithm With Enhanced Accuracy for Surveillance of Deep Surgical Site Infections After Elective Colorectal Surgery. A Diagnostic Accuracy Study.","Infect-IA-2","Inclusion Criteria:\n\n* Elective colorectal resection\n\nExclusion Criteria:\n\n* Emergency surgery\n* Infection present at operation\n* Previous intestinal stoma",{"count":377,"type":22},1200,"Epidemiological surveillance is one of the eight core components of the World Health Organization Infection Prevention and Control Programmes. These include surveillance programmes for surgical site infection (SSI).\n\nAt present, for SSI surveillance, infection control teams perform a manual time-consuming work, which could make a transition to automated surveillance leveraging the new information technology.\n\nThe aim of this study was to evaluate the performance of a novel algorithm to detect SSI in a cohort of elective colorectal surgery patients who have been previously screened within a nationwide healthcare-associated infection surveillance system.",[28],[28,381,382,383],"Surveillance","Articicial inteligence","Algorithms","2025-08-19",{"date":386,"type":33},"2025-08-24",{"date":388,"type":33},"2025-01-15",{"date":390,"type":22},"2025-10-30",{"name":392,"class":78},"Hospital de Granollers",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":412,"leadSponsor":414,"locationsCount":41},"100564224","chatgpt-4-for-surgical-site-infection-detection-from-electronic-health-records-after-colorectal-surgery-100564224","NCT06626399","ChatGPT-4 for Surgical Site Infection Detection From Electronic Health Records After Colorectal Surgery.","Evaluation of ChatGPT-4 for the Detection of Surgical Site Infections From Electronic Health Records After Colorectal Surgery: A Diagnostic Accuracy Study.","Infect-IA-3",{"count":314,"type":22},"Epidemiological surveillance is one of the eight core components of the World Health Organization Infection Prevention and Control Programmes. These include surveillance programmes for surgical site infection (SSI).\n\nAt present, for SSI surveillance, infection control teams perform a manual time-consuming work, which could make a transition to automated surveillance leveraging the new information technology.\n\nThis study aimed to evaluate the ability of ChatGPT-4o to detect surgical site infection at the three anatomical levels.",[28],[404,381,405,406,407],"Surgical site infection","ChatGPT","Natural language processing","Artificial inteligence","2025-08-12",{"date":410,"type":33},"2025-08-15",{"date":388,"type":33},{"date":413,"type":22},"2025-11-30",{"name":392,"class":78},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":17,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":426,"conditions":427,"keywords":432,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":41},"100328836","early-phase-1-zinc-oxide-versus-petrolatum-following-skin-surgery-100328836","NCT03561376","Zinc Oxide Versus Petrolatum Following Skin Surgery","Zinc Oxide Versus Petrolatum Following Skin Surgery: A Head-to-head, Prospective, Split-scar Study","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Linear closure, non-scalp site\n3. ≥ 4.5 cm in length (final incision\u002Fclosure length)\n4. End to end symmetry (surgical site is not grossly asymmetric from end to end)\n5. Grossly uninfected site\n\nExclusion Criteria:\n\n1. ≤ 18 years\n2. Visibly asymmetric linear scar\n3. Grossly infected surgical site\n4. History of allergy to topical zinc oxide",{"count":423,"type":22},30,[425],"EARLY_PHASE1","Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patients will apply respective ointments to each half of scar daily for one month and maintain a log of these activities. They will be seen at 1 week, 4 weeks, 8 weeks, and 6 months post-operatively for photographic scar assessment and to complete the patient portion of the Patient and Observer Scar Assessment Scale (POSAS), a quantitative objective assessment of scar appearance. Trained observers (board-certified dermatologists) will score the observer portion of the scale. POSAS outcomes, post-operative infections, linear density of epidermal seal will be assessed at the 1 week, 4 weeks, 8 weeks, and 6 months post-operative periods and compared between the two groups. Participants will have parking validated for all visits and upon completion of all portions of the study will receive a standardized skin care gift bag containing samples for hypoallergenic skin care products (washes, moisturizers, etc.).",[287,428,429,28,430,431],"Surgery--Complications","Surgical Wound","Scar","Hypertrophic Scar",[430],{"date":434,"type":33},"2025-08-14",{"date":436,"type":33},"2021-09-01",{"date":438,"type":22},"2026-10-30",{"name":440,"class":78},"Melissa Pugliano-Mauro",{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":41},"100566031","a-novel-surgical-irrigation-solution-in-post-mastectomy-reconstruction-evaluating-xperience-100566031","NCT06649890","A Novel Surgical Irrigation Solution in Post-Mastectomy Reconstruction: Evaluating Xperience™","A Randomized Control Trial Evaluating the Efficacy of Xperience™ Surgical Irrigation Solution Versus Dilute Povidone-Iodine in Preventing Surgical Site Infections and Improving Postoperative Outcomes in Implant-Based Breast Reconstruction","Inclusion Criteria:\n\n* Older than 18 years old\n* Willing to comply with all study-related procedures\n* Available for the duration of the study\n* Participants undergoing double mastectomy surgery followed by one of the following: (1) Immediate reconstruction with tissue expander placement, (2) Delayed reconstruction with tissue expander or implant placement, (3) Immediate reconstruction with implant placement, (4) Second-stage reconstruction with tissue expander to implant exchange\n\nExclusion Criteria:\n\n* Participants unable to participate in follow-up visits\n* Participants undergoing unilateral mastectomy\n* Tissue expanders placed by a surgeon outside of the UNC Chapel Hill Hospital System\n* Undergoing autologous reconstruction\n* Participant is unable to provide signed and dated informed consent\n* Unwilling or unable to comply with all study-related procedures.\n* Known history of sensitivity or allergic reaction to any of the components of the Xperience™ irrigation solution or dilute povidone-iodine irrigation\n* Participant with any conditions that would be a contraindication to receiving surgery such as contraindications to general anesthesia\n* Pregnant, planning to become pregnant or breast feeding participants\n* Individuals providing informed consent with any mental impairment or condition that would make them unable to properly consent without use of legally authorized representative (LAR) or additional participant protections.\n* Incarcerated participants",{"count":449,"type":22},224,[25],"Goal of the Clinical Trial:\n\nThe purpose of this clinical trial is to learn whether Xperience™ surgical irrigation solution is more effective than a standard dilute povidone-iodine solution in reducing surgical site infections (SSIs) following implant-based breast reconstruction in female patients, aged 18 and older. It will also assess the safety and overall surgical outcomes when using Xperience™ compared to povidone-iodine.\n\nMain Questions the Study Aims to Answer:\n\n* Does the use of Xperience™ decrease the incidence of surgical site infections compared to povidone-iodine?\n* What are the differences in the rates of premature implant removal due to infection between patients treated with Xperience™ and those treated with povidone-iodine?\n* Are there fewer post-surgical complications with Xperience™ compared to povidone-iodine?\n\nStudy Design:\n\nParticipants in this study will be randomly assigned to receive either Xperience™ or a dilute povidone-iodine solution during their bilateral implant-based breast reconstruction. Only the research team will know which irrgiation is given- the participant will not know.\n\nParticipant Will:\n\n* Undergo the surgical procedure using one of the two irrigation solutions.\n* Receive regular post-operative check-ups to monitor for signs of infection and other complications.\n* Have data collected on any post-surgical complications, the necessity for early implant removal, and overall surgical outcomes.",[28,453,454,455],"Surgical Complication","Implant Infection","Implant Complication","2025-08-06",{"date":458,"type":33},"2025-08-07",{"date":460,"type":33},"2025-06-30",{"date":462,"type":22},"2028-06-30",{"name":464,"class":78},"University of North Carolina, Chapel Hill",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":477,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":484,"locationsCount":215},"100484341","phase-4-decolonization-to-reduce-after-surgery-events-of-surgical-site-infection-100484341","NCT05586776","Decolonization to Reduce After-Surgery Events of Surgical Site Infection","DECREASE SSI","Inclusion Criteria:\n\n* 18 years of age or older\n* Recent open (not solely laparoscopic) surgery involving an abdominal incision within the past 14 days. For cesarean section, recruitment restricted to BMI ≥ 40.\n* Able to communicate regularly by phone\n* Able to bathe, shower or have this task performed by a caregiver\n\nExclusion Criteria:\n\n* Transfer to an acute care hospital\n* Discharged to receive end-of-life hospice measures\n* Discharged more than 14 days after surgery\n* Allergic to mupirocin and\u002For chlorhexidine\n* Active infection at enrollment\\*\n\n  \\*Refers to\n  1. Infections requiring systemic antibacterial agents, so viral illness (e.g., COVID, flu) is not an exclusion.\n  2. Topical antibacterial agents do not count toward exclusion (e.g., topical products for acne)\n  3. Prophylactic antibacterial agents do not count toward exclusion\n* Surgical incision not closed at discharge",{"count":473,"type":22},2700,[88],"The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce SSI.",[28],[28,352],"2025-07-23",{"date":480,"type":33},"2025-07-28",{"date":482,"type":33},"2023-01-17",{"date":211,"type":22},{"name":485,"class":78},"University of California, Irvine",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":50,"enrollmentInfo":493,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":41},"100515275","phase-2-outcomes-of-high-volume-saline-irrigation-vs-povidone-iodine-solution-cleaning-of-iowi-in-preventing-ssis-in-emergency-laparotomies-100515275","NCT05989386","Outcomes of High-volume Saline Irrigation VS Povidone-Iodine Solution Cleaning of IOWI in Preventing SSIs in Emergency Laparotomies","Outcomes of High-volume Saline Irrigation VS Povidone-Iodine Solution Cleaning of Intraoperative Incision Wound in Preventing Surgical Site Infections in Emergency Laparotomies: A Randomized Controlled Trial","Inclusion Criteria:\n\n* • Patients undergoing emergency laparotomy under the care of surgical-6 unit of Dr. Ruth K. M. Pfau Civil Hospital Karachi\n\n  * The age of patients should be between 18-60 years old.\n\nExclusion Criteria:\n\n* Diabetic patients\n* Immune-suppressed patients\n* Patients taking steroids\n* Patients undergoing chemo-radiotherapy.\n* Pregnant females\n* Previous abdominal surgery within the last 30 days.\n* Presence of concurrent abdominal wall infections.\n* Trauma Laparotomies\n* Large Bowel perforations",{"count":494,"type":22},200,[496,316],"PHASE2","The goal of this clinical trial is to compare the outcomes of High-volume saline irrigation vs Povidone-iodine solution cleaning of the intraoperative incision wound in preventing superficial surgical site infections in patients undergoing emergency laparotomies. The main question it aims to answer are:\n\n* Incidence of SSI after intervention\n* Length of hospital stay\n\nParticipants will be randomly assigned to two groups receiving either of the two groups:\n\nGroup A: 1000ml of IOWI with saline solution prior to incision closure Group B: The incisional wound will be closed conventionally without irrigation.\n\nResearchers will compare groups A( experimental group) and B (control group) to compare the incidence of superficial surgical site infections after intervention.",[28,429,287,499,500,501,146,502],"Emergency Laparotomies","Laparotomies","Post Operative Wound Infection","Seroma","2025-06-14",{"date":505,"type":33},"2025-06-18",{"date":507,"type":33},"2023-04-29",{"date":509,"type":22},"2025-12-29",{"name":511,"class":78},"Dow University of Health Sciences",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":17,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":526,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":41},"100539863","phase-4-ostomy-primary-closure-with-01-betainepolyhexanide-wound-irrigation-compared-to-pursestring-closure-100539863","NCT06309368","Ostomy Primary Closure With 0.1% Betaine\u002FPolyhexanide Wound Irrigation Compared to Pursestring Closure","To Close or Not to Close: Surgical Site Infection Rates in Ostomy Primary Closure With 0.1% Betaine\u002FPolyhexanide Wound Irrigation Compared to Conventional Ostomy Closure by Secondary Intention","Inclusion Criteria:\n\n* All patients 18 years or older with an diverting loop ileostomy reversal indication will be enrolled\n* Signed consent\n\nExclusion Criteria:\n\n* Under 18 years old, unable to provide consent, has a parastomal hernia requiring mesh repair, or has an end ileostomy",{"count":520,"type":22},84,[88],"The goal of this clinical trial is to compare two types of closure in patients with ostomies that are ready for closure. The main questions it aims to answer are:\n\n1. Surgical site infection rates\n2. Patient quality of life\n3. Time to wound healing\n\nParticipants will undergo either complete ostomy wound closure after washing out the wound with Prontosan, or their ostomy wound will be closed using the Pursestring method, where the wound will be left partially open and allowed to heal from the inside out. Researchers will compare these two groups' outcomes (questions to be answered) as listed above.",[28,524,525],"Wound Surgical","Colorectal Disorders",[527,28,528,529],"Ostomy","Primary Closure","Secondary Closure","2025-05-27",{"date":532,"type":33},"2025-06-02",{"date":534,"type":33},"2024-03-14",{"date":536,"type":22},"2029-12",{"name":538,"class":78},"University of Nevada, Las Vegas",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":41},"100586804","phase-4-prevention-of-trauma-related-infections-through-an-embedded-clinical-trials-network-100586804","NCT06920147","PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network","PRevention Of Trauma-related Infections Through an Embedded Clinical Trials (PROTECT) Network","PROTECT","Inclusion Criteria:\n\n* Trauma laparotomy within 90 minutes of arrival\n\nExclusion Criteria:\n\n* Patients with a known allergy to cephalosporins or β-lactamase inhibitors\n* Prisoners\n* Pregnant and lactating women",{"count":548,"type":22},300,[88],"The purpose of this study is to compare the effectiveness of 2 prophylactic antibiotic regimens, ertapenem and cefazolin with metronidazole, in preventing organ space surgical site infections (OS-SSI) after emergency trauma laparotomy embedded into routine clinical care and to validate a Bayesian OS-SSI risk calculator using Trauma Quality Improvement Program (TQIP) standardized variables",[28],"2025-04-08",{"date":554,"type":33},"2025-04-11",{"date":556,"type":22},"2025-05-01",{"date":558,"type":22},"2027-03-31",{"name":560,"class":78},"The University of Texas Health Science Center, Houston",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":568,"targetDuration":4,"studyType":23,"phases":570,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":41},"100550987","subcutaneous-lavage-in-cesarean-section-100550987","NCT06454227","Subcutaneous Lavage in Cesarean Section","Antiseptic Washing Prior to Skin Closure During Cesarean Delivery- a Randomized Control Trial","Inclusion Criteria:\n\n* pregnant women undergoing cesarean delivery\n\nExclusion Criteria:\n\n* pregnant women undergoing vaginal delivery",{"count":569,"type":22},600,[25],"The goal of this clinical trial is to learn if antiseptic washing prior to skin closure during cesarean section reduces rates of surgical site infection.\n\nintraoperative washing is a common practice in other surgical fields and several studies have shown efficacy in reducing postoperative infection rates. no randomized control trial has tested this intervention during cesarean section.\n\nThe main questions we aim to answer are:\n\nDoes subcutaneous antiseptic washing reduce the rates of surgical site infection? Does antiseptic washing improve scar healing? Does antiseptic washing reduce hospital stay, postpartum fever rates and readmission cases?\n\nResearchers will compare subcutaneous antiseptic washing to no intervention to see if surgical site infection rates reduce\n\nParticipants will:\n\nconsent to participate in the trial Visit the postpartum clinic 30 days after surgery",[28],"2025-03-17",{"date":575,"type":33},"2025-03-19",{"date":577,"type":33},"2024-09-22",{"date":579,"type":22},"2028-12-01",{"name":581,"class":78},"Hadassah Medical Organization",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":49,"minAge":590,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":23,"phases":594,"briefSummary":595,"conditions":596,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":611,"locationsCount":613},"100382220","phase-3-perioperative-respiratory-care-and-outcomes-for-patients-undergoing-high-risk-abdominal-surgery-100382220","NCT04256798","Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery","PErioperative Respiratory Care and Outcomes for patieNts Undergoing hIgh Risk abdomiNal Surgery: A 2x2 Factorial, International Pragmatic Randomised Controlled Trial Across Low and Middle-income Countries","PENGUIN","Inclusion Criteria:\n\n* Adults and children aged 10 years or over\n* Elective or emergency abdominal surgery via midline laparotomy with an anticipated abdominal incision of at least 5cm in length\n* Written informed consent of patient (signature or a fingerprint)\n\nExclusion Criteria:\n\n* Patients undergoing caesarean section\n* Patients with a documented or suspected allergy to chlorhexidine\n* Patient unable to complete postoperative follow-up (not contactable after discharge)\n* Previous enrolment in PENGUIN within the past 30 days\n* American Society of Anesthesiologists (ASA) grade V patients (expected to die with or without surgery)","10 Years","100 Years",{"count":593,"type":22},12942,[316],"PENGUIN is a pragmatic multi-center trial investigating the effects of pre-operative mouthwash and perioperative oxygen on the incidences of pneumonia and surgical site infection (SSI) following major abdominal surgery.\n\nPatients will be recruited from low and middle income countries and randomly assigned to a trial treatment arms: a) pre-operative chlorhexidine mouthwash and 80-100% FiO2; b) no pre-operative mouthwash and 80-100% fraction of inspired oxygen (FiO2); c) pre-operative chlorhexidine mouthwash and 21- 30% FiO2; or d) no pre-operative mouthwash and 21-30% FiO2.",[597,598,28,146,599,228,600,601,602,603,123,604],"Infection","Pneumonia","Surgical Wound Infection","Anesthesia","Communicable Disease","Pathologic Processes","Perioperative Complication","Laparotomy","2025-02-18",{"date":607,"type":33},"2025-02-19",{"date":609,"type":33},"2020-11-13",{"date":70,"type":22},{"name":612,"class":78},"University of Birmingham",37,{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":49,"minAge":590,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":23,"phases":624,"briefSummary":625,"conditions":626,"keywords":627,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":41},"100528720","disposable-versus-reusable-drapes-and-gowns-for-green-operating-theatres-100528720","NCT06164444","Disposable Versus Reusable DrApes and Gowns for Green OperatiNg Theatres","Multicentre Non-inferiority Cluster Randomised Trial Testing Disposable Versus Reusable DrApes and Gowns for Green OperatiNg Theatres","DRAGON","Inclusion criteria:\n\n* Patients with at least one incision that is ≥5cm in adults and ≥3cm in children aged under 16 years. This can include both open and minimally-invasive surgery providing at least one incision meets this criteria.\n* Patients with a clean-contaminated, contaminated, or dirty surgical wound. Definitions of contamination are given in Table 2.\n* Patients undergoing emergency (surgery on an unplanned admission) or elective (surgery on a planned admission) surgery.\n* Any operative indication (including caesarean section).\n* Patients aged 10 or over.\n\nExclusion criteria\n\n* Adults with an incision \\\u003C5 cm and incision \\\u003C3cm in children aged under 16 years.\n* Patients undergoing procedures with a clean surgical wound only.",{"count":623,"type":22},26800,[25],"Multicentre non-inferiority cluster randomised trial testing Disposable versus Reusable drApes and Gowns for green OperatiNg theatres. A pragmatic 1:1 international multi-centre non-inferiority cluster randomised controlled trial, with an internal pilot. Clusters are individual hospitals.",[28],[628,629,352,66],"Surgery","global surgery","2025-02-14",{"date":607,"type":33},{"date":633,"type":33},"2024-11-12",{"date":635,"type":22},"2026-07-31",{"name":612,"class":78},{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":645,"conditions":646,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":4},"100578003","dixon-mri-imaging-histology-for-predicting-postoperative-infection-in-posterior-lumbar-fusion-for-myasthenia-gravis-100578003","NCT06805643","Dixon MRI Imaging Histology for Predicting Postoperative Infection in Posterior Lumbar Fusion for Myasthenia Gravis","Inclusion Criteria:\n\n* Male and female patients over 18 years of age.\n* Inclusion of patients with sarcopenia is subject to the definition and diagnostic criteria of the European Consensus on Definition and Diagnosis of Sarcopenia.\n* The patient underwent posterior lumbar fusion and had a Dixon MRI scan within 2 weeks prior to surgery.\n* Patients were able to understand the purpose and procedures of the study and were willing to sign an informed consent form.\n* The patient's clinical consultation and follow-up information was complete.\n\nExclusion Criteria:\n\n* The patient has contraindications to MRI, such as implanted metal devices (e.g., pacemakers) or severe claustrophobia.\n* Patients with serious other medical conditions, such as heart disease, kidney disease or liver disease, which may affect their post-operative recovery.\n* Patients have known immune system disorders or are on immunosuppressive therapy, which may affect their risk of infection.\n* The patient has had other spinal surgery within the last 6 months.",{"count":644,"type":22},1300,"Sarcopenia is an age-related condition that manifests itself as a persistent decrease in muscle mass and function, which may lead to decreased physical function, increased risk of disease, and reduced quality of life. In surgical patients, sarcopenia has been shown to be associated with increased postoperative complications, prolonged hospitalization, and decreased survival. In patients undergoing lumbar fusion, the presence of sarcopenia may increase the risk of postoperative infection.Lumbar fusion is a common procedure to treat lumbar spine disorders such as lumbar disc herniation, lumbar spondylolisthesis, or lumbar spinal stenosis. However, this procedure is associated with a high rate of complications, especially postoperative infections, which can lead to reoperation, prolonged hospitalization, and even affect patient survival. In recent years, more and more studies have found a significant association between sarcopenia and postoperative infections after lumbar fusion surgery.Imagingomics belongs to a branch of machine learning, which is the process of acquiring images from various imaging devices such as CT, MRI and ultrasound, outlining the region of interest through image segmentation, extracting the features of the image within the region of interest, downscaling the features, and finally building an imagingomics model. MRI Imagingomics, utilizing its rich data information, has shown great potential for application in several medical fields. Among them, the accuracy of Dixon MRI imaging histology in muscle mass and texture assessment makes it particularly important in predicting postoperative infections.Based on this, it is reasonable to believe that Dixon MRI imaging histology can be a powerful tool to help us predict a patient's risk of postoperative infection.",[647,28,648],"Lumbar Vertebrae","Radiomics","2025-01-28",{"date":651,"type":33},"2025-02-03",{"date":653,"type":22},"2025-02",{"date":655,"type":22},"2026-02-28",{"name":657,"class":78},"The First People's Hospital of Yunnan",{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":664,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":666,"targetDuration":4,"studyType":23,"phases":668,"briefSummary":669,"conditions":670,"keywords":672,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":41},"100565160","postoperative-basal-bolus-or-sliding-scale-insulin-regimen-in-dm2-and-its-effect-on-surgical-site-infections-100565160","NCT06638567","Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site Infections.","Postoperative Glucose Control with a Basal Bolus Versus Sliding Scale Insulin Regimen and Its Effect on the Incidence of Surgical Site Infections in People with Type 2 Diabetes Mellitus.","GUIDE","Inclusion Criteria:\n\n* Patients aged 18 or older\n* Diagnosed with type 2 diabetes mellitus\n* Undergoing gastointestinal or vascular surgery\n* Admitted to one of the participating surgical wards\n* Expected duration of stay at least one overnight stay\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed with type 1 diabetes mellitus\n* Female of child-bearing potential who is pregnant or breastfeeding.\n* Undergoing complete pancreatectomy\n* Undergoing bariatric surgery\n* Patients using a continuous insulin pump at home\n* Patients undergoing a necrotectomy\u002Fwound debridement from a pre-existent wound.",{"count":667,"type":22},1008,[25],"A multicentre, matched-pair, cluster randomised controlled superiority trial to investigate the effect of a proactive basal bolus insulin regimen compared to the reactive sliding scale insulin regimen, targeting a glucose level of 3.9-10.0 mmol\u002FL, to reduce the number of surgical site infections within the first 30 days postoperatively in adult patients with diabetes mellitus type 2.",[671,28],"Diabetes Mellitus, Type 2",[673,674,675,676,677],"Diabetes Mellitus","Basal bolus regimen","Surgical site infections","Sliding scale","Insulin regimen",{"date":679,"type":33},"2025-01-30",{"date":681,"type":33},"2025-01-03",{"date":683,"type":22},"2027-09",{"name":685,"class":78},"Abraham Hulst, MD, PhD"]